For a 1.0 mg per 120 mg core immediate-release mecobalamin tablet, the primary technical boundary is not dissolution but delivery of a low-dose light-sensitive API with uniform distribution across a direct-compression blend. Under USP <905> Uniformity of Dosage Units, the acceptance value must not exceed 15.0, and batch agreement for methylcobalamin tablets is typically compelled to be tighter because segregation at 0.83% w/w can shift individual units outside the 85.0–115.0% label-claim window if pre-blending is omitted. Compliance documentation for this finished product type includes 21 CFR 211.160 laboratory controls, ICH Q3D elemental impurity permitted daily exposures, ICH Q3C residual solvent classes, and the JP 18 Methylcobalamin monograph for identity, assay, and related substances by liquid chromatography. Published data for this specific light-protected dry-blend configuration is limited; the open-bulk hold-time boundary is therefore set by in-house photostability screening rather than a pharmacopoeial numeric requirement.

Formulation addition ratio for the direct-compression process is 0.50–1.00% w/w depending on dose and core mass; a 0.5 mg dose in a 100 mg core is 0.50% w/w, while a 1.0 mg dose in a 120 mg core is 0.83% w/w. Because mecobalamin is heat-labile and hygroscopic, wet granulation is not performed; instead, the API is geometrically triturated with a 1:1 portion of mannitol or microcrystalline cellulose, passed through a 30 mesh (600 µm) stainless-steel sieve, and then dispersed into a 500 L bin blender at 10–15 rpm for 20–30 minutes. The pre-blend is charged with crospovidone 2–5% w/w as superdisintegrant, colloidal silicon dioxide 0.5% w/w, and magnesium stearate 1.0% w/w; lubrication is limited to 3–5 minutes because excessive shear can coat the API and retard dissolution in USP <711> Apparatus 2 testing at 50 rpm in 900 mL water. Compression is performed on a rotary tablet press fitted with 7 mm round D-tooling, with compression force adjusted to 8–14 kN; higher force compacts low-density mannitol and lowers porosity below the threshold at which disintegration exceeds 15 minutes. The production suite is fitted with sodium vapour or amber lighting, and unprotected bulk hold times under white light are not permitted to exceed 30 minutes before compression. The finished product type is a round, film-coated immediate-release tablet packaged in aluminium/aluminium blister to retain both photoprotection and moisture barrier.

Capsule-Fill Content Uniformity Under Photodegradation Stress

Hard-capsule filling of mecobalamin at a label claim of 0.5 mg or 1.0 mg uses the same JP 18 API monograph as tablet manufacture, but finished-product documentation must additionally address shell moisture, photoprotection, and fill weight control under 21 CFR 211.160. The addition ratio is lower than in tablets because a size 1 HPMC capsule typically carries a nominal fill mass of 180 mg; therefore 0.5 mg corresponds to 0.28% w/w and 1.0 mg corresponds to 0.56% w/w. At this dilution, direct fill is used rather than wet granulation. Compliance requirements for the capsule finished product type include USP <905> Uniformity of Dosage Units, USP <711> dissolution for hard-shell capsules, ICH Q3D elemental impurity limits, and ICH Q1B photostability for blister package selection.

The API is first pre-screened through a 40 mesh (425 µm) sieve with a 10-fold portion of pregelatinized starch or anhydrous lactose, then dry-blended in a tumble blender at 12–15 rpm for 20 minutes. The blend is filled into HPMC shells on a dosator-type capsule filling machine operating at 40,000–80,000 capsules/h; capsule shell conditioning is maintained at 20–25°C and 35–45% RH to prevent brittle fracture and static-induced segregation of API fines. The production bottleneck observed with this route is hopper feed stratification: when API D90 is below 75 µm and the bulk blend has a Hausner ratio above 1.45, die-bed density fluctuation generates capsule weight RSD values above 4% unless head-load vibratory feed adjustment is applied. The finished product type is a hard HPMC capsule in a PVC/PVDC/aluminium or all-aluminium blister; the outer foil is selected after ICH Q1B photostability testing, with confirmation of not more than 1.2 million lux hours and 200 Wh/m² visible and UV exposure.

Why Is API-Free Granulation the Default Route for Mecobalamin Sachet Granules?

Aqueous granulation of methylcobalamin at wet-bulb product temperatures above 40°C creates a photolytic and hydrolytic degradation risk that is not recoverable by post-drying overage adjustment. The sachet granule form is manufactured as 0.5 mg or 1.0 mg per 1.0 g unit dose; this addition ratio is only 0.05% w/w or 0.10% w/w, placing the API below the threshold where direct blending into placebo granules without geometric pre-blending is acceptable. Compliance for this finished product type includes the JP 18 General Rules for Granules, ICH Q3D elemental impurity limits, ICH Q3C residual solvent limits, and 21 CFR 211.160 distribution testing of the final sachet.

The placebo granulation is produced first on a top-spray fluid-bed granulator. A mixture of mannitol, microcrystalline cellulose, and pregelatinized starch is sprayed with an aqueous binder solution of povidone K30 at 3–5% w/w; inlet air is set at 65–70°C and product temperature is held at 30–35°C. After spray completion, granules are dried to loss-on-drying below 2.0% and milled through a 1.0 mm screen. The API is not introduced into the binder; it is pre-blended with a 10-fold portion of non-hygroscopic mannitol, screened through a 50 mesh (300 µm) sieve, and then blended with the cooled granules at 12 rpm for 15 minutes. The resulting mixture is filled into aluminium/aluminium/polyethylene sachets at 20–25°C and less than 30% RH to avoid dust generation and static separation of the API from the carrier granules. The finished product type is a single-dose oral granule sachet for direct oral dosing or dispersion in water.

Aqueous injectable solution of mecobalamin is treated as an aseptic-filtration product, not a terminally moist-heat-sterilized product, because methylcobalamin degrades rapidly when held at sterilisation temperatures above 100°C in buffered media; the cobalt-carbon bond undergoes homolytic cleavage to hydroxocobalamin under light and dissolved oxygen stress. The addition ratio is 0.5 mg per 1.0 mL (0.05% w/v), and the formula is compounded with 0.9% sodium chloride or another tonicity adjuster in water for injection, with pH adjusted into the stability window of 5.5–6.5 using dilute hydrochloric acid or sodium hydroxide. Compliance requirements for this finished product type include 21 CFR 211.113 microbiological contamination control, 21 CFR 211.167 sterility testing, USP <1> Injections, USP <85> Bacterial Endotoxins, USP <788> Particulate Matter in Injections, Ph. Eur. 2.6.14 bacterial endotoxins, and EU GMP Annex 1 for aseptic processing.

Manufacturing is performed under Class A laminar flow with a Grade B background. Water for injection is sparged with nitrogen until dissolved oxygen is below 0.5 ppm, the API is dissolved at 20–25°C under low-actinic red light, and the bulk solution is passed through a 0.22 µm PVDF sterilising filter whose retention is validated to ASTM F838-20. The filtered solution is filled into 1 mL Type I amber glass ampoules or vials with headspace nitrogen purge at a residual oxygen concentration below 1.0%. Bulk solution hold time is not permitted to exceed 8 hours at 20–25°C before filtration is completed. The finished product type is a clear red solution for intramuscular or intravenous administration after aseptic filtration, not a terminally autoclaved solution.

Direct Compression of Sublingual Mecobalamin Imposes a Low-Force and Fast-Disintegration Operating Envelope

Sublingual administration of mecobalamin requires a tablet that disintegrates in less than 30 seconds when tested by USP <701> Disintegration at 37°C in purified water, but the low-dose API and the high proportion of water-soluble filler create a direct-compression conflict: increasing compression force to reduce friability below 1.0% simultaneously increases disintegration time above the intended 30-second limit. The API addition ratio is 0.83% w/w for a 1.0 mg dose in a 120 mg core and 0.50% w/w for a 0.5 mg dose in a 100 mg core. Compliance documentation includes USP <701> Disintegration, USP <905> Uniformity of Dosage Units, Ph. Eur. 2.9.1 Disintegration, 21 CFR 211.160, and ICH Q1B photostability for package selection.

The formulation uses co-processed mannitol and crospovidone at 5–8% w/w as superdisintegrant; API is pre-blended in a 1:1 trituration with mannitol and passed through a 30 mesh (600 µm) sieve before final mixing. Compression is performed on a rotary tablet press with 8 mm flat-faced bevel-edge punches at 8–12 kN. Hardness is maintained at 25–45 N, and friability is measured by rotating 100 tablets at 25 rpm for 4 minutes in a USP friabilator; the acceptance criterion is not more than 1.0% weight loss. Processing area relative humidity is held below 40% because the co-processed mannitol and crospovidone matrix absorbs moisture and shifts disintegration time upward; pre-drying of excipients is required if storage RH exceeds 60%. The finished product type is a sublingual orally disintegrating tablet sealed in low-moisture aluminium peel-push blisters.